Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Denise Cotting"'
Autor:
Edward Cha, Melissa Lynne Johnson, Pakeeza Sayyed, Farah Louise Lim, Enriqueta Felip, Johanna C. Bendell, Kyu-Pyo Kim, Xiaosong Zhang, Yoon-Koo Kang, Do-Youn Oh, Hans-Joachim Helms, Simon Allen, Osama E. Rahma, Teresa Macarulla, J. Pintoffl, Gulam Abbas Manji, Byoung Chul Cho, Denise Cotting, Nathan Bahary
Publikováno v:
Cancer Research. 80:CT201-CT201
Background: The MORPHEUS platform comprises multiple Phase Ib/II trials to identify early efficacy signals and safety of treatment combinations across cancers. Within MORPHEUS, atezolizumab (atezo), a PD-L1 inhibitor, was tested in combination with c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6cf9e683dc7e979f210e205e3a4da766
https://doi.org/10.1158/1538-7445.am2020-ct201
https://doi.org/10.1158/1538-7445.am2020-ct201
Autor:
David MacDonald, Klaas Veenstra, Sirpa Leppä, Mark Dixon, Santiago Mercadal, Martin Barrett, Denise Cotting, Andrew Davies, Georgi Mihaylov, Artem Zharkov, Biljana Mihaljevic
Publikováno v:
Blood. 128:1103-1103
Background: A new subcutaneous formulation of rituximab (RSC) has been developed which offers reduced treatment burden for patients compared to intravenous rituximab (RIV) as well as resource savings at the treatment facility. Additionally, availabil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da6b964e7936cb096460be4dab6dfee2
https://doi.org/10.1182/blood.v128.22.1103.1103
https://doi.org/10.1182/blood.v128.22.1103.1103
Autor:
Denise Cotting, C. Droege, Silke Gillessen, Ralph Winterhalder, Dirk Klingbiel, Miklos Pless, Ralph Schiess, Rolf Jaggi, Peter Brauchli, Richard Cathomas, Lukas Bubendorf, Daniele Siciliano, Daniel Betticher, Christian Rothermundt, Roger von Moos, Dominik Berthold
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 18(21)
Purpose: The EGF receptor (EGFR) is overexpressed in the majority of metastatic castration-resistant prostate cancers (mCRPC) and might represent a valid therapeutic target. The combination of docetaxel and cetuximab, the monoclonal antibody against
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e04279ec1eae78a2442bc7c864827b26
https://pubmed.ncbi.nlm.nih.gov/22977195
https://pubmed.ncbi.nlm.nih.gov/22977195